Behavioral disorders secondary to profound hypomagnesemia in a patient given cetuximab for metastatic colorectal cancer hypomagnesemia due to cetuximab treatment

By Perrin Christophe   Fabre Cédric   Raoul Jean-Luc   Boucher Eveline  

Acta Oncologica, Vol. 45, Iss. 8, 2006-12 ,pp. : 1135-1136

Informa Healthcare

Access to resources Recommend Favorite

Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A metaanalysis

By          

Oncology Letters, Vol. 5, Iss. 6, 2013-01 ,pp. : 1915-1920

Spandidos Publications

Access to resources Recommend Favorite

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab

By  

Oncology Letters, Vol. 9, Iss. 3, 2015-01 ,pp. : 1432-1438

Spandidos Publications

Access to resources Recommend Favorite

Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer

By Larsen Finn Ole   Pfeiffer Per   Nielsen Dorte   Skougaard Kristin   Qvortrup Camilla   Vistisen Kirsten   Fromm Anne-Lene   Jøørgensen Trine L.   Bjerregaard Jon K.   Hoegdall Estrid   Jensen Benny V.  

Acta Oncologica, Vol. 50, Iss. 4, 2011-05 ,pp. : 574-577

Informa Healthcare

Access to resources Recommend Favorite

Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin

By                                    

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1029-1034

Science Publishers

Access to resources Recommend Favorite